NCT02426437

Brief Summary

Chronic obstructive pulmonary disease (COPD) is a chronic lung disease primarily caused by smoking. COPD creates a tremendous burden to the healthcare system, as disease exacerbations result in frequent, prolonged hospitalizations. While originally considered a disease specific to the lung, data has shown that COPD is associated with substantial cardiovascular (CV) morbidity and mortality. Exacerbations of COPD requiring hospitalization result in marked patient deterioration, and heightened CV risk. The cause of the increased CV risk with stable COPD, and the exaggerated CV risk during exacerbations of the disease are unknown; however, it may be due to chronic inflammation which is exacerbated with a flare-up of the disease, and/or chronic inactivity which is similarly worsened with bed-rest during a hospitalization. Despite the impact of COPD on healthcare, there are relatively few studies examining how COPD inpatient care impacts on patient outcomes, inflammation and CV risk. Disease management programs, such as pulmonary rehabilitation and patient self-management education, are part of guideline therapy for COPD; however, these are not regularly implemented following a hospitalization, and how these interventions affect patient outcomes, behavior, physical activity, inflammation and CV risk have not been well studied. The proposed long-term project will examine how early referral to chronic disease management programs after hospital discharge, affect patient outcomes. This study will provide invaluable information about outpatient management for a disease which has a tremendous impact on healthcare.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
87

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Feb 2015

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2015

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

March 17, 2015

Completed
1 month until next milestone

First Posted

Study publicly available on registry

April 27, 2015

Completed
4.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2019

Completed
Last Updated

April 8, 2021

Status Verified

April 1, 2021

Enrollment Period

4.8 years

First QC Date

March 17, 2015

Last Update Submit

April 7, 2021

Conditions

Keywords

Acute Exacerbation of COPD (AECOPD)COPDEmphysemaChronic Bronchitis

Outcome Measures

Primary Outcomes (5)

  • Change in Quality of Life - 1

    Quality of Life - 1 will be assessed using the COPD Assessment tool.

    Change from Baseline Quality of Life - 1 at 8 weeks and 6 months

  • Change in Vascular Function

    Vascular function will be assessed using peripheral arterial tone (PAT)

    Change from Baseline Vascular Function at 8 weeks and 6 months

  • Change in Central and Peripheral Arterial Stiffness (AS)

    Arterial Stiffness will be assessed using pulse wave velocity measured from the carotid and femoral (central) and carotid and radial (peripheral) arteries.

    Change from Baseline Central and Peripheral Arterial Stiffness (AS) at 8 weeks and 6 months

  • Change in Quality of Life - 2

    Quality of Life - 2 will be assessed using the St. George Respiratory Questionnaire.

    Change from Baseline Quality of Life - 2 at 8 weeks and 6 months

  • Change in Quality of Life - 3

    Quality of Life - 3 will be assessed using the COPD Self Efficacy Scale.

    Change from Baseline Quality of Life - 3 at 8 weeks and 6 months

Secondary Outcomes (5)

  • Change in Inflammatory marker (IL-6)

    Change from Baseline IL-6 at 8 weeks and 6 months

  • Change in Inflammatory marker (TNF-alpha)

    Change from Baseline TNF-alpha at 8 weeks and 6 months

  • Change in Inflammatory Marker (MMP-2)

    Change from Baseline MMP-2 at 8 weeks and 6 months

  • Change in Inflammatory markers (CRP)

    Change from Baseline CRP at 8 weeks and 6 months

  • Change in Dyspnea (breathlessness)

    Change from Baseline Dyspnea at 8 weeks and 6 months

Study Arms (3)

Early Pulmonary Rehabilitation (EPR)

OTHER

Patients randomized to EPR will be enrolled into the Breath Easy pulmonary rehabilitation (PR) program at the Centre for Lung Health within 1 month of discharge. They will proceed through the program in a typical fashion.

Other: Pulmonary Rehabilitation (PR)

Late Pulmonary Rehabilitation (LPR)

OTHER

Patients randomized to LPR will be enrolled into the Breath Easy pulmonary rehabilitation (PR) program at the Centre for Lung Health within 3 months of discharge. They will proceed through the program in a typical fashion.

Other: Pulmonary Rehabilitation (PR)

Usual Care

OTHER

Usual care patients will be followed-up by their most responsible physician as determined by the admitting team.

Other: Usual Care

Interventions

Patients enrolled in PR will undergo a 6-8 week rehabilitation program.

Early Pulmonary Rehabilitation (EPR)Late Pulmonary Rehabilitation (LPR)

Patients enrolled in usual care will be followed-up by their most responsible physician as determined by the admitting team.

Usual Care

Eligibility Criteria

Age50 Years - 85 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • All patients admitted to the pulmonary ward for an AECOPD will be offered participation into this arm of the study.

You may not qualify if:

  • Acute cardiac injury during admission
  • Mobility issues
  • Residence outside the greater Edmonton area

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Alberta Hospital

Edmonton, Alberta, T6G2B7, Canada

Location

MeSH Terms

Conditions

Pulmonary Disease, Chronic ObstructiveEmphysemaBronchitis, Chronic

Condition Hierarchy (Ancestors)

Lung Diseases, ObstructiveLung DiseasesRespiratory Tract DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and SymptomsBronchitisRespiratory Tract InfectionsInfectionsBronchial Diseases

Study Officials

  • Michael K Stickland, PhD

    University of Alberta

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 17, 2015

First Posted

April 27, 2015

Study Start

February 1, 2015

Primary Completion

December 1, 2019

Study Completion

December 1, 2019

Last Updated

April 8, 2021

Record last verified: 2021-04

Locations